Show simple item record

dc.contributor.advisorHutt, Peter Bartonen_US
dc.contributor.authorHeinonen, Mikkoen_US
dc.date.accessioned2012-06-07T20:38:50Z
dc.date.issued2002en_US
dc.identifier.citationDisclosure of the Dealings Between Drug Developing Companies and the FDA Under the Federal Securities Laws (2002 Third Year Paper)en
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:8852181
dc.description.abstractThe purpose of this article is to highlight the main issues raised by the Food and Drug Administration’s (“FDAâ€) approval process relating to new drugs and the treatment of this process receives in the context of the Federal Securities Laws . The partial inspiration for this article has been the recent highly publicized case concerning ImClone Systems Incorporated – a case, which well exemplifies both the connection between the valuation of a biotech/medical company and the FDA’s approval process for new drugs, and also the huge effect of the approval process to the market’s valuation of the stock price.en
dc.language.isoen_USen
dash.licenseLAAen_US
dc.subjectFood and Drug Lawen
dc.subjectFDAen
dc.subjectsecuritiesen
dc.subjectdisclosureen
dc.subjectapprovalen
dc.subjectImCloneen
dc.titleDisclosure of the Dealings Between Drug Developing Companies and the FDA Under the Federal Securities Lawsen
dc.typePaper (for course/seminar/workshop)en_US
dc.date.available2012-06-07T20:38:50Z
dash.authorsorderedfalse


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record